Video

Giuliana Rancic: Finding the Light at the End of the Tunnel

Entertainment journalist and breast cancer survivor Giuliana Rancic shared her cancer journey before she presented at the 2019 Extraordinary Healer Award for Oncology Nursing.

Best known for her work on E! News, Giuliana Rancic revealed her ability to find the light at the end of the tunnel following her breast cancer journey.

Before the 2019 Extraordinary Healer Award for Oncology Nursing, Rancic shared on her cancer journey, assuring other women that they are not alone. “Something that helped me were the four words, ‘This too, shall pass’. With every little tough moment I was having, I would keep falling back on that. Just knowing that it’s going to get better, knowing that it’s OK to feel scared, it’s OK to be sad, it’s OK to wake up in the middle of the night and be terrified. It’s so normal and so many people feel the way you do.”

Cancer-free for seven years, she also discussed the hardest years of her journey with breast cancer. “It was very hard for me to feel like I could go back to a life without thinking about breast cancer 100 times a day,” Rancic said. “And I’m living proof that it can happen.”

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
a man and a woman in front of a dark blue background
a man and a woman in front of a dark blue background
Related Content